Eagle Pharmaceuticals (EGRX) Reports Q2 Loss of $0.12
Tweet
Share
E-mailGet Alerts EGRX Hot Sheet
Join SI Premium – FREE
Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.12). Revenue for the quarter came in at $48.71 million versus the consensus estimate of $53.87 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi raises Atlassian price target to $225, maintains Buy rating
- JPMorgan Downgrades Li Ning Co. Ltd. (2331:HK) (LNNGF) to Neutral
- Citi raises Adobe price target to $301, keeps neutral rating
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
